$MANE

CHILDS JOHN W sold $10.7M of MANE (indirect holdings)

CHILDS JOHN W sold 100,000 indirectly-held shares of Veradermics, Inc (MANE) at an average of $107.12 ($106.14–$108.24, $10.71M total) across 3 trades on 2026-08-12.

Original reporting
SEC EDGAR · CHILDS JOHN W
Published Aug 14, 2026, 10:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 10:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MANE
Neutral
medium confidence
Mentioned
$MANE
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MANENeutralLow
01

Why it matters

A director’s open-market sale of 100,000 shares at about $106.14 to $108.24 is disclosed, but there is no accompanying guidance, deal, or operational update.

02

Market read

Traders may note insider selling as a sentiment datapoint, but the filing alone is unlikely to drive a durable repricing without additional fundamental news.

03

What to watch

The article does not disclose the insider’s cost basis, tax situation, or whether other insiders are selling, limiting inference from this single transaction.

Relevance 7/10Novelty 3/10Timing: filed 2026-08-14 after-hours; sale executed 2026-08-12

Background

The article is an SEC Form 4 insider transaction disclosure for Veradermics, Inc (MANE).

Company-level read

Ticker impact

$MANENeutralMedium confidence
Context

Director CHILDS JOHN W sold $10.71M of MANE shares via an open-market sale on 2026-08-12, with holdings after sale at 194,117 shares.

Expected impact

Low near-term impact; any effect is likely sentiment-driven and limited unless follow-on selling or new fundamentals emerge.

Evidence & confidence

The filing discloses transaction size, price range, and post-sale holdings, but provides no new company-specific operating or regulatory catalyst.

Market effects

No sector read-through is provided beyond a single-company insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for diversification or liquidity needs; the absence of a stated 10b5-1 plan does not necessarily imply negative expectations.

Key entities

  • Veradermics, Inc

    Company whose director insider sale is reported on SEC Form 4.

  • CHILDS JOHN W

    Director who sold shares indirectly via open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MANEMed

Veradermics, Inc (MANE): Results of Operations and Financial Condition

Veradermics, Inc (MANE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991q226earnings.htm EX-99.1 Document Exhibit 99.1 Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Positive topline results from open-label Phase 2 Study ‘207’ evaluating VDPHL01 in female pattern hair los

$MANEMedAI 8/10

Veradermics' Oral Hair Loss Drug For Women Shows Results In Just 2 Months - Veradermics (NYSE:MANE)

Veradermics (NYSE:MANE) reported positive Phase 2 results for VDPHL01 in women with female pattern hair loss. In a 6-month study at 4.5 mg once daily or twice daily, hair count increased about 22.7 and 23.3 hairs/cm², respectively. By month six, 88.9% and 90% reported improved coverage, with no treatment-related serious adverse events. Shares were up 15.01% to $126.71.

$MANEMedAI 8/10

Extended-Release Oral Minoxidil Posts First Efficacy Win in Women With Hair Loss

Veradermics (NYSE: MANE) said its extended-release oral minoxidil tablet VDPHL01 showed clinically meaningful hair growth in women with female pattern hair loss in Phase 2 Study 207. In 22 women over 6 months, once-daily and twice-daily doses increased non-vellus hair counts by 22.7 and 23.3 hairs/cm², with no treatment-related serious adverse events. Enrollment for Study 306 continues; topline expected H1 2027.

$MANEMedAI 8/10

Veradermics stock rises 9% on positive hair loss trial data By Investing.com

Veradermics (NYSE:MANE) shares rose about 9% after the company reported positive Phase 2 results for VDPHL01, its oral treatment for female pattern hair loss. Study 207 showed 88.9% (once daily) and 90.0% (twice daily) had improved outcomes at Month 6, with no treatment-related serious cardiac events reported through then. Topline results for Study 306 are expected in H1 2027.